You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- The number of new cases continues to rise, and new restrictions are being implemented. As the pandemic remains a major threat, the development of a new vaccine is imperative. Paul Mango, Deputy Chief of Staff for Policy for Health and Human Services Secretary Alex Azar, repeated the administration's position: that all Americans who want to be vaccinated against the virus will be able to do so by early spring 2021. Yet, recent delays from vaccine manufacturers make it unclear how soon we can expect one. Just earlier this week, Pfizer reported that the first interim analysis in its Phase 3 clinical trial has not yet occurred. A report by STAT also indicates that AstraZeneca, which in June anticipated it could begin to supply up to 2 Billion doses of vaccine in September, instead saw its Phase 3 trials in several countries put on hold when a participant experienced neurological symptoms that chairman Pascal Soriot said were consistent with transverse myelitis. Johnson & Johnson, the only manufacturer among the major vaccine makers testing a one-dose Covid vaccine, also saw its Phase 3 trial paused for two weeks after a volunteer in his 20s suffered what the Washington Post stated to be a stroke. Todos Medical Ltd.(OTC:TOMDF), Pfizer Inc.(NYSE:PFE), Gilead Sciences, Inc. (NASDAQ: GILD), Vaxart, Inc.(NASDAQ:VXRT), Moderna, Inc. (NASDAQ: MRNA) "While it's unfortunate, I don't find it surprising that the timeline is being moved back," said Michael Osterholm, Director of the University of Minnesota's Center for Infectious Diseases Research and Policy. "Clinical trials like this routinely have unexpected occurrences that delay planned timelines. It's just not unexpected." Therefore, in the meantime, to properly combat the virus and avoid further restrictions, effective mass scale testing is crucial. Overall, three companies gained authorization from the Food and Drug Administration (FDA) to sell antigen testing instruments to labs or clinics. Additionally, a fourth company, Abbott Laboratories, also won approval to market a specific USD 5 rapid test administered by a health care professional. Yet, there are no tests that have yet been approved to be sold directly to consumers. Overall, testing continues to be uneven, as some states have managed to provide higher rates of testing than others. In addition, various companies are racing to develop antibody tests, also called serological tests, that can confirm whether someone was infected even after their immune system has cleared the virus. Todos Medical Ltd.(OTCQB:TOMDF) announced breaking news last week that, "it has selected the brand name "Tollovid" for its proprietary, patent protected 3CL protease inhibitor, previously called NLC-001. Todos licensed the exclusive worldwide distribution rights for Tollovid, excluding Israel, from Israel-based joint venture partner NLC Pharma in September 2020. Tollovid is an orally administered proprietary blend of plant extracts that includes a powerful 3CL protease inhibitor that helps support and maintain healthy immune function. The 3CL protease plays a vital role in the intracellular replication of coronaviruses, and 3CL protease inhibition is being evaluated as a potential therapeutic target for COVID-19 by several groups, including Pfizer. Concurrent with this announcement, the Company announced that it has entered into a private label and distribution agreement with The Alchemist's Kitchen, based in the SoHo district of New York City with a significant online presence. The Alchemist's Kitchen is New York's leading botanical wellness destination, leveraging the power of plants to improve health while working closely with leading clinicians and medical doctors to educate patients on how to use natural remedies to improve their health in the face of illness or disease. The Alchemist's Kitchen has been featured in several high-profile educational series, including Dr. Sanjay Gupta's CBD and cannabis specials that were previously featured on CNN. The Alchemist's Kitchen will sell Tollovid under its Plant Alchemy brand and will train its herbalists to help educate consumers on how adding Tollovid to their immune boosting strategy could potentially lead to improved outcomes in the face of circulating coronaviruses. 'Tollovid certainly is a unique asset in the botanical wellness space, and we are very pleased to be the first to bring this product to market in the United States,' said Lou Sagar, President & CEO of The Alchemist's Kitchen. 'It's clear there has been a tremendous amount of science developed around Tollovid as it relates to 3CL inhibition, and we believe this could be an important mechanism during this critical time heading into the colder months of the year where people will congregate indoors more often. As a brand, The Alchemist's Kitchen is always looking to be on the cutting edge of innovation in the botanical wellness space, and Tollovid certainly reinforces our market leading position.' 'We are excited to have selected the brand name Tollovid for NLC-001 and to be partnering with The Alchemist's Kitchen to bring this important immune-boosting dietary supplement into the marketplace at this critical time in the United States,' said Gerald E. Commissiong, President & CEO of Todos Medical. 'Some of the most promising data in the scientific literature to date in combatting coronaviruses has been generated by dietary supplements that help reinforce the body's ability to respond to potential challenges from a coronavirus infection. We are targeting Tollovid to be added to this immune-boosting paradigm, and believe Tollovid could be an important part of an immune boosting strategy to help support and maintain a healthy immune system during this upcoming period of significant concern about potential circulating viruses heading into the colder weather months ahead.' For information related to Todos Medical's COVID-19 testing capabilities, please visit www.todoscovid19.com For our latest "Buzz on the Street" Show featuring Todos Medical Ltd. recent corporate news, please head over to: https://www.youtube.com/watch?v=FZB5eRAEk3I&ab_channel=FinancialBuzzMedia Pfizer Inc.(NYSE:PFE) announced onAugust 7th, a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer'sMcPherson, Kansasfacility to manufacture and supply remdesivir for Gilead. In March, Pfizer launched a five-point plan, which called on all members of the innovation ecosystem from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to commit to work together in addressing the dire COVID-19 crisis. "From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer's agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions," saidAlbert Bourla, Chairman and Chief Executive Officer. "Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible." Gilead Sciences, Inc. (NASDAQ: GILD) announced earlier last month that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury(remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States. The drug is now widely available in hospitals across the country, following early investments to rapidly expand manufacturing capacity to increase supply. "The approval of Veklury marks an important milestone in efforts to help address the pandemic by offering an effective treatment that helps patients recover faster and, in turn, helps preserve scarce healthcare resources," said Barry Zingman, MD, Professor of Medicine at the Albert Einstein College of Medicine and Montefiore Medical Center, New York. "The availability of a rigorously tested treatment that can significantly speed recovery and offers other benefits such as lower rates of progression to mechanical ventilation, provides hospitalized patients and their families important hope and offers healthcare providers a critical tool as they care for patients in need." Vaxart, Inc.(NASDAQ:VXRT) announced back in September that theU.S. Food and Drug Administration(FDA) has completed its review of the Company's Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. The Company also provided an update on its COVID-19 program. "Our goal is to deliver the best, most elegant solution for conferring mass protection against COVID-19. Our oral tablet vaccine offers a much more attractive mode of administration than injectables and may confer superior protection against COVID-19 due to activation of mucosal immunity. Importantly, our room-temperature stable tablet is significantly easier and cheaper to store and distribute to the farthest corners of the US and the globe, as it does not require the very costly and complex refrigerated cold chain needed for injectable vaccines.," saidAndrei Floroiu, chief executive officer ofVaxart. "The IND clearance and the initiation of our Phase 1 clinical trial moves us a step closer to proving the superiority of our convenient oral COVID-19 solution in the clinic. We are thus excited to start enrollment for our Phase 1 this month." Moderna, Inc. (NASDAQ: MRNA) confirmed last week that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., Ltd have agreed to purchase and distribute 50 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to support Japan's aim of providing vaccines to the Japanese public as soon as possible, subject to necessary regulatory approvals. Moderna is responsible for the manufacture and supply of Moderna's vaccine candidate, and Takeda, with the support of the MHLW, the Japan Agency for Medical Research and Development (AMED) and Moderna, is responsible for all import, local regulatory, development and distribution activities in Japan to ensure timely access starting during the first half of 2021. "We thank the MHLW and Takeda for their support and for partnering with us to bring mRNA-1273, our vaccine candidate against COVID-19, to Japan. We appreciate the confidence of the MHLW in Moderna and mRNA-1273, which we hope will help address the pandemic, especially given the encouraging data we have recently published together with the NIH related to the clinical trial in the elderly and older adult population," said Stphane Bancel, Moderna's Chief Executive Officer. "We look forward to our expected first review of our interim efficacy data, which is expected in November." Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMediaFollow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzzFollow and talk to us on Instagram: https://www.instagram.com/financialbuzzFacebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/ About FinancialBuzz.com FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications. Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For todos medical ltd. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has signed a six-month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has agreed to five million restricted shares, FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com. Media Contact:[emailprotected]+1-877-601-1879www.FinancialBuzz.com SOURCE FinancialBuzz.com

Answer: Vaccine Development Holdups Reinforce the Need for Interim Solutions FinancialBuzz.com News Commentary